Division of Infectious Diseases, Montefiore Medical Center,
Bronx, New York 10467,1 and Howard
Hughes Medical Institute, Department of Microbiology and Immunology,
Albert Einstein College of Medicine, Bronx, New York
104612
 |
INTRODUCTION |
New therapies are urgently needed to
treat Mycobacterium tuberculosis, one of the leading causes
of death from a single infectious disease worldwide (15).
Although this pathogen can be treated effectively with multidrug
therapy (1), incomplete treatment has led to the development
of drug-resistant strains (17, 30). In general, antibiotics
that inhibit cell wall biosynthesis are among the most effective agents
against bacterial pathogens. In the case of M. tuberculosis,
a number of highly effective antibiotics including isoniazid (INH) and
ethambutol work by inhibiting biosynthesis of the mycobacterial cell
wall. Because the cell wall is an attractive target for antibiotic
development, considerable effort has been focused on discovering the
metabolic steps that are essential for biosynthesis of cell wall
components (10, 11, 23, 28). The enzymatic targets of many
cell wall active antibiotics also have been discovered recently
(7, 12, 25, 38).
Despite progress in characterizing the mycobacterial cell wall, very
little is known about the intracellular mechanisms that are activated
as a consequence of cell wall injury. Antibiotic-induced cell death may
involve events that are not directly related to inhibition of the
primary antibiotic target. For example, autolysins are activated when
cell wall biosynthesis is inhibited by
-lactam antibiotics in many
gram-positive bacteria (13, 19, 39). Microarray technology
has revealed that diverse sets of genes are induced following treatment
of cells with drugs (14, 42). In the case of M. tuberculosis, novel antibiotics that directly target these
pathways may be highly effective in the treatment of disease due to
this organism, either alone or synergistically with other cell
wall-active agents. The identification of promoters that are
specifically induced by cell wall damage could also be valuable as part
of a screen that used reporter assays to discover novel cell
wall-active compounds (25).
In the course of studying the differential gene expression of M. tuberculosis in response to INH, we discovered three INH-induced genes organized in tandem on the M. tuberculosis genome that
we termed iniB, iniA, and iniC
(3). We postulated that all three ini genes
comprised a single operon, iniBAC. Northern blot and reverse
transcription-PCR experiments demonstrated that the iniA gene was induced by both INH and ethambutol (3), two
antibiotics that act on the cell wall by different mechanisms (7,
12, 25, 38). The kasA gene has been shown to be
induced by INH and the related compound ethionamide (25,
42). However, no mycobacterial promoters that are induced by
unrelated antibiotics targeting different pathways of cell wall
biosynthesis have been identified. Little is known about the structure
of regulated promoters in M. tuberculosis. The inducible
promoters that have been characterized in M. tuberculosis
include promoters for the sigma factors sigB (20)
and sigF (27), the DNA repair protein
recA (26), and the response regulator
mtrA (41). In the case of recA, a
putative upstream activation sequence has been identified, and a
Cheo-like box that binds to the transcriptional repressor LexA has been found (26). Here, we demonstrate that the promoter of the
putative iniBAC operon is specifically induced by a broad
range of inhibitors to cell wall biosynthesis including antibiotics
that inhibit the synthesis of (i) peptidoglycan (ampicillin and
ampicillin/sulbactam [24]), (ii) arabinogalactam
(ethambutol [12, 38]), (iii) mycolic acids (INH,
ethionamide, and 2-alkynoic acid [KOAs]), and (iv) fatty acids
(5-chloropyrazinamide [5-chloro-PZA]) (7, 25; O. Zimhony et al., unpublished data). We characterize the nature of the
induction and demonstrate the suitability of the promoter to screen for
cell wall-active antibiotics using luciferase reporter plasmids. The
structure of the promoter is investigated and likely regulatory
sequences are identified.
 |
MATERIALS AND METHODS |
Bacteria and culture methodology.
Escherichia coli
DH5
(33) was used for all plasmid constructions. E. coli cultures were grown at 37°C in Luria-Bertani medium
(33) with the addition of hygromycin B (200 µg/ml; Sigma, St. Louis, Mo.) or kanamycin (40 µg/ml; Sigma) where appropriate. Mycobacterium bovis BCG Pasteur and BCG Montreal strains
ATCC 35735 and ATCC 35747, and M. smegmatis strain
mc2155 (34) were grown at 37°C on a rotary
shaker in Middlebrook 7H9 medium (Difco, Detroit, Mich.) containing
0.05% Tween 80, 0.02% glycerol, and 10% oleic-albumin dextrose
complex (Becton Dickinson, Cockeysville, Md.), with the addition of
hygromycin B (50 µg/ml) for strains containing pYUB509-based
constructs or kanamycin (24 µg/ml) for mc2155 strains
containing pCV125-based constructs. For induction experiments,
additional antibiotics were added at the indicated final
concentrations. BCG and mc2155 strains were cultured in
150-cm2 tissue culture flasks (Corning, Cambridge, Mass.)
at 100 ml per flask, starting from 1:100 dilutions of strain stocks.
Cultures were grown to an optical density at 590 nm (OD590)
of approximately 0.4, except for experiments specifically designed to
examine promoter induction at various ODs. The cultures were then split
into 30-ml square medium bottles (Nalgene, Rochester, N.Y.) at 5 ml per
bottle, antibiotics and other reagents were added to the growing
cultures as indicated, and the cultures were then returned to the
incubator. Culture aliquots were removed at specified time points for
luciferase or
-galactosidase assays.
Sequence positions.
The sequence numbering used in this
study corresponds to the M. tuberculosis genomic sequence
position (16; National Center for Biotechnology
Information [NCBI] database
[http://www.ncbi.nlm.nih.gov/cgi-bin/Entrez/framik?db=Genome&gi=135]). By this convention, the iniB gene (Rv0341 or
MTCY13E10.01) starts at 409354, the iniA gene (Rv0342
or MTCY13E10.02) starts at 410824, and the iniC gene (Rv0343
or MTCY13E10.03) starts at 412755. The translational start sites
designated in this investigation vary slightly from previous annotations.
Plasmids and strains.
The plasmids and strains used in this
study are listed in Table 1. Plasmid
pYUB509, containing lacZ and fflux reporter
genes, was used to construct pG4697-6 and pG1697-3 for testing
iniBAC promoter activity in luciferase and
-galactosidase
assays (Table 1). Plasmid pG4697-6, which contained a sequence
beginning 211 bp upstream of the first iniBAC open reading
frame (iniB) extending to the translational start site, was
transformed into the antibiotic-susceptible BCG Montreal strain ATCC
35735 (BCGS) to create strain BCGS(pG4697-6).
Plasmid pG4697-6 was also transformed into the INH-resistant BCG
Montreal strain ATCC 35747 (BCGR), which contains a
deletion in the katG gene, to create strain BCGR(pG4697-6). Plasmid pG1697-3, which contained the same
211-bp region in the reverse orientation, was transformed into
BCGS to create strain BCGS(pG1697-3). Plasmid
pCV125, an integrating vector containing kanamycin resistance and a
promoterless lacZ gene, was obtained from MedImmune (Gaithersburg, Md.). This plasmid was used as the basis for constructs aimed at testing the activity of partial promoter deletions. Fourteen plasmids were constructed by ligating successive 5' or 3' deletions of
the 211-bp sequence upstream of iniB into pCV125 (Table 1). These 14 plasmids were transformed into M. smegmatis strain
mc2155 to create strains mc2155(pG4799-1)
through mc2155(pG4799-12), mc2155(pG15499-1),
and mc2155(pG15499-2). The finished plasmid constructs
were subjected to automated DNA sequencing in order to exclude
mutations that could occur during the PCR or cloning process. The
unpublished plasmid pKB15 was a gift of Graham Hatfull, this
integrating plasmid carries the fflux gene under control of
the L5 phage pL promoter, resulting in
constitutive expression of luciferase. Plasmid pKB15 also contains
hygromycin and ampicillin resistance genes and L5 attP,
int, and oriE. pKB15 was transformed into BCG
Pasteur, resulting in strain BCG(pKB15).
Chromosomal DNA and RNA extraction.
Chromosomal DNA from
different mycobacterial species was extracted using a sodium dodecyl
sulfate (SDS)-hexadecyltrimethylammonium bromide (Fisher, Pittsburgh,
Pa.) protocol as described previously (2). For RNA
preparation, BCG strain ATCC 35735 was grown to an OD590 of
0.5. INH was then added to the culture for a final concentration of 1.0 µg/ml, or the culture was allowed to continue without added INH.
After an additional 18-h incubation, RNA was extracted using a TRIzol
(Life Technologies, Gaithersburg, Md.) based protocol as described
previously (3).
PCR generation of amplicons.
PCRs were performed in 50-µl
volumes containing either 10 ng of chromosomal DNA or 1 ng of plasmid
DNA with 2.5 mM each deoxynucleosides triphosphate, 20 pmol each of
upstream and downstream primers, 1.25 U of Taq polymerase
with a final concentration of 1× PCR buffer (Gibco BRL, Grand Island,
N.Y.), and 2 mM MgCl2. DNA was amplified in an Applied
Biosystems Geneamp 9700 thermal cycler (Perkin-Elmer, Foster City,
Calif.) for 30 cycles of 94°C for 1 min, annealing at 55°C for 1 min, and 72°C for 1 min, followed by 72°C for 10 min.
Luciferase assays.
At specified time points, 25 µl of each
culture was removed and added to 75 µl of 7H9 medium in a glass
cuvette (Lumacuvette-P; Celsis-Lumac, Landgraaf, The Netherlands).
Luciferase activity was measured using 40 mM luciferin (Sigma) in 1 M
C6H5Na3O7 · 2H2O (pH 4.5) in a Lumac 2010A luminometer (Celsis-Lumac)
according to the manufacturer's recommendations. Induction was
calculated as follows: relative light units (RLU) for sample
culture/RLU for medium-only control culture, if RLU for sample > RLU for control. A decrease in luciferase activity of the sample
culture compared to the control culture (repression) was calculated as
RLU for control/RLU for sample.
-Galactosidase assays.
At specified time points, 500 µl
of each culture was set aside on ice for subsequent measurement of the
OD590. An additional 500 µl of each culture was
simultaneously removed and added to 500 µl of Z buffer (60 mM
Na2HPO4 · 7H2O, 40 mM
NaH2PO4 · H2O, 10 mM KCl, 1 mM MgSO4 · 7H2O, 50 mM
-mercaptoethanol, adjusted to pH 7.0) in a 2-ml microcentrifuge
tube. Two drops of chloroform and one drop of 0.1% SDS were then
added, and the tubes were vortexed for 30 s. The tubes were
incubated at 28°C for 5 min, 200 µl of fresh
o-nitrophenyl-
-D-galactopyranoside (ONPG) (4 mg/ml; Sigma) in Z buffer was added to each tube, and the tubes were
shaken well and incubated at 28°C. When a faint yellow color appeared in the control tube (5 to 20 min), the reaction was stopped with 0.5 ml
of 1 M Na2CO3 and spun in a microcentrifuge at
top speed for 5 min, and the OD420 of the supernatant was
measured.
-Galactosidase units were calculated using the formula
1,000 × OD420/time (minutes) × 0.5 × OD590.
Primer extension.
Oligonucleotide primers were end labeled
with [
32P]ATP at their 5' ends, using T4
polynucleotide kinase as described in the primer extension kit
(Promega, Madison, Wis.); 0.1 pmol of labeled primer was annealed to
6.5 µg of total RNA at 75°C for 0.5 h. Extension was carried
out with avian myeloblastosis virus reverse transcriptase (Promega)
according to the manufacturer's instructions at 42°C for 0.5 h.
The reactions were added to 20 µl of loading dye (98% [vol/vol]
formamide, 10 mM EDTA, 0.1% xylene cyanol, 0.1% bromophenol blue) and
denatured at 90°C for 10 min. The reaction products were then run on
an 8% polyacrylamide-urea sequencing gel. Bands were visualized by
autoradiography. Sequencing reactions were carried out by cycle
sequencing (Perkin-Elmer) according to the manufacturer's instructions.
Southern blots.
Genomic DNA from different mycobacterial
species was digested with PvuII, subjected to
electrophoresis in a 0.7% agarose gel, and transferred by capillary
action to Biotrans Plus nylon membranes (ICN Pharmaceuticals, Costa
Mesa, Calif.). The blots were prehybridized at 50°C in Rapid-Hyb
buffer (Amersham, Arlington Heights, Ill.) and then hybridized
overnight with [
32P]dCTP-radiolabeled (Megaprime
labeling kit; Amersham) probes. The probe complementary to a 400-bp
segment of the iniA gene was generated by PCR using the
primers iniART-T and iniART-B. The probe complementary to the entire
iniB gene was generated by a BamHI-NruI digestion of pG7897-4 (Table 1). The
blots were washed in progressively more stringent conditions until
autoradiography revealed clear bands and minimal background hybridization.
Statistical analysis.
Mean induction or repression and 95%
confidence internals were calculated using Microsoft Excel 97 software.
 |
RESULTS |
Induction of the iniBAC promoter.
The discovery
that the iniA gene was induced by ethambutol as well as INH
(3) suggested that induction was not specific to inhibition
of mycolic acid biosynthesis. Integrating reporter plasmids containing
the iniBAC promoter fused to the genes encoding luciferase
and
-galactosidase were constructed to further investigate the
induction characteristics. The iniA gene appeared to be the second gene in a three-gene operon consisting of iniB,
iniA, and iniC. We chose to investigate the
promoter activity of the sequence extending 211 bp upstream of
iniB to the translational start site of iniB
(positions 409142 to 409353). BCGS(pG4697-6), which
contained the full-length 211-bp sequence, was cultured to log phase
and then split into untreated portions or portions that were treated
with antibiotics and other reagents. Induction was assessed by
comparing luciferase activity in the treated portions to that in the
untreated control. Significant induction occurred in the presence of
many different cell wall-active agents despite the divergence of their
known mechanisms of action (Fig. 1A).
After 24 and 48 h of incubation with antibiotics, induction by INH, ethambutol, ethionamide, 5-chloro-PZA, and KOA was 10- to
30-fold greater than control cultures. Induction by ampicillin, and by
the combination
-lactam-
-lactamase inhibitor Unasyn
(ampicillin/sulbactam), was consistently three- to fivefold greater
than in control cultures. Induction by INH was reversed by coincubation
with rifampin, indicating that the induction was due to increased rates
of transcription. Among the cell wall biosynthesis inhibitors tested,
only cycloserine did not result in induction of the reporter.


View larger version (3619K):
[in this window]
[in a new window]
|
FIG. 1.
Effects of different compounds on iniBAC
promoter activity as measured by luciferase assays of integrated
transcriptional fusion plasmids. Induction is shown after incubation
with compounds for 24 h (grey bars) or 48 h (black bars).
Final concentrations are indicated in micrograms per milliliter. Error
bars represent 95% confidence intervals. (A) INH-susceptible
BCGS(pG4697-6) containing the iniBAC promoter
fused to lacZ and fflux genes [-Pro indicates
assays performed with BCGS(pG1697-3), which contains the
same construct, except that the transcriptional fusion was performed by
inserting the promoter in the opposite orientation from the coding
region]. (B) INH-susceptible BCG(pMKB15) containing the L5 phage
pL promoter fused to the fflux gene.
(C) INH-resistant BCGR(pG4697-6) containing the
iniBAC promoter fused to lacZ and
fflux genes.
|
|
To ensure that the observed induction was not simply due to luciferase
release into the media by cell wall-active antibiotics, the experiments
were repeated with BCG(pKB15), a BCG strain which expressed luciferase
constitutively. In contrast to BCGS(pG4697-6), luciferase
expression in the BCG(pKB15) cultures decreased or remained unchanged
under all experimental conditions (Fig. 1B). The results demonstrate
that the 211-bp sequence immediately upstream of the iniB
gene contains the promoter for the putative iniBAC operon.
Induction of this promoter was specific to antibiotics that inhibit
cell wall biosynthesis. The promoter was either not induced or
repressed by other biological stresses, including hydrogen peroxide,
heat shock, acidosis, and the antibiotics kanamycin, ciprofloxicin, and
rifampin, that do not directly inhibit cell wall biosynthesis (Fig.
1A). Induction also was not observed after incubation with
paraminosalicylic acid, an antituberculosis drug with an unknown
mechanism of action. Importantly, disruption of the cell wall by
lysozyme or granulysin also led to repression rather than induction of
luciferase activity. These findings demonstrate that induction of the
iniBAC promoter was due to inhibition of cell wall
biosynthesis and could not be caused simply by lysis or disruption of
the cell wall.
Next, induction was assessed using the INH-resistant strain
BCGR(pG4697-6), which contains the same luciferase reporter
construct as BCGS(pG4697-6) but is INH resistant due to a
deletion in the katG gene. The katG gene encodes
catalase-peroxidase, which is required to convert INH into its active
form (43). Induction by INH was not observed with this
strain; however, it remained inducible in the presence of other
antibiotics (Fig. 1C). This demonstrated that induction was due to the
biological activity of INH and was not due to nonspecific effects of
the unactivated compound. This conclusion is supported by the
observation that induction was observed only at antibiotic
concentrations at or above their MICs (Fig.
2). Induction did not increase further at
concentrations above the MIC, although maximum induction occurred more
rapidly at the higher concentrations.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 2.
Induction of the iniBAC promoter in
BCGS(pG4697-6) after incubation with INH for 24 ( ) and
48 ( ) h and with ethambutol for 24 ( ) and 48 ( ) h.
|
|
One inhibitor of cell wall biosynthesis, cycloserine, appeared to
result in repression of luciferase expression. However, treatment with
cycloserine resulted in rapid cell lysis, a phenomenon that was not
observed with the other antibiotics. Induction experiments were
repeated with diminishing doses of cycloserine, but induction was not
detected at any concentration of this drug. A lacZ reporter system is less dependent on full viability of the cells at the time of
the induction assay (40). Induction experiments using ONPG
to measure
-galactosidase activity also failed to consistently detect induction by cycloserine (data not shown). In contrast, all of
the other inhibitors of cell wall biosynthesis resulted in induction
when measured by
-galactosidase assay.
Induction kinetics.
The time course of iniBAC
promoter induction after incubation with antibiotics was tested by
incubating BCGS(pG4697-6) with INH (1 µg/ml) or
ethambutol (5 µg/ml) and assessing serial aliquots for luciferase
activity. Induction was apparent as early as 4 h after incubation
with either antibiotic, reaching a maximum between 25 and 48 h
(Fig. 3).

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 3.
Induction of the iniBAC promoter in BCG
strain BCGS(pG4697-6) after incubation with INH (1 µg/ml;
) and ethambutol (5 µg/ml; ) as a function of incubation
time.
|
|
The effect of the growth phase of the culture on induction was also
studied. We speculated that ATP levels might be dependent on growth
phase; therefore,
-galactosidase assays were used to measure
induction in these experiments. BCGS(pG4697-6) was
grown from a highly diluted culture until it reached stationary phase.
Two aliquots were removed from the culture every 24 h starting at
an OD590 of 0.1. Ethambutol was added to one of the paired
aliquots, then both were reincubated for an additional 24 h, and
-galactosidase activity was measured. These experiments demonstrated
that iniBAC promoter activity increased slowly as the
OD590 of the culture increased (Fig.
4). However, induction by ethambutol
occurred only during log-phase growth and disappeared when the cultures
reached stationary phase. Similar induction characteristics were
observed after incubation with INH (data not shown).

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 4.
Induction in different phases of growth.
BCGS(pG4697-6) was subcultured by performing a 1:100
dilution of an actively growing culture. Serial aliquots were removed
at increasing OD590 and split into paired subcultures. One
subculture of each pair was not treated with antibiotics ( ); the
other subculture of each pair was treated with ethambutol at a final
concentration of 5 µg/ml ( ). After an additional 24 h,
-galactosidase activity was measured. -Galactosidase units are
shown as a function of the OD590 of the paired subcultures
at the time that they were removed from the parent culture.
|
|
Species distribution of the iniBAC operon.
We
previously determined that INH induced the iniA genes from
both M. tuberculosis H37Rv and BCG (3). The
211-bp promoter region was sequenced in BCG strain ATCC 35735. Alignment with the corresponding sequence in M. tuberculosis
strain H37Rv (16; NCBI database) revealed that the
two sequences were 100% identical. Because mycobacterial species have
similar cell wall structures, the presence of the iniBAC
operon in different species of mycobacteria was assessed. Two probes
were used, one complementary to a 400-bp region of the iniA
gene and the other complementary to the entire iniB gene.
The radiolabeled probes were hybridized separately to Southern blots
containing genomic digests of three M. tuberculosis strains
(Erdman, H37Rv, and H37Ra), of mycobacterial strain BCG, and of
M. smegmatis (strain mc2155), M. avium, M. marinum, M. microti, and M. nonchromogenicum. The iniA probe hybridized strongly to
single bands in all of the species except M. avium and
M. nonchromogenicum. Hybridization to the M. nonchromogenicum genomic DNA resulted in two weak bands (Fig.
5). The iniB probe also failed
to hybridize to M. avium, although it hybridized strongly to
all of the other species except M. marinum. A control probe
complementary to a region of the M. tuberculosis 16S rRNA
gene hybridized to all of the species tested.

View larger version (81K):
[in this window]
[in a new window]
|
FIG. 5.
Testing of the iniBAC operon in different
mycobacterial species. Mycobacterial species were tested by
low-stringency Southern blot hybridization for the presence of the
iniA and iniB genes: M. marinum (lane
1), H37ra (lane 2), M. tuberculosis strains Erdman (lane 3)
and H37Rv (lane 4), M. avium (lane 5), BCG (lane 6),
M. smegmatis (lane 7), M. nonchromogenicum (lane
8), and M. microti (lane 9). (A) Agarose gel showing
PvuII digests of chromosomal DNA. (B) Southern blot of the
gel in panel A hybridized with the iniA gene probe. (C)
Hybridization with the M. tuberculosis 16S RNA gene probe.
(D) Hybridization with the iniB gene.
|
|
Mapping the transcriptional start site of the BCG
iniBAC operon.
The transcriptional start site for the
operon was determined by primer extension analysis in order to better
understand the structure of the promoter region. Total RNA was
extracted from BCGS grown in the presence or absence of INH
during the last 18 h of culture. Primer extension was performed
with both samples using iniBprimer ext-3, which is complementary to the
first 21-bp of the translated M. tuberculosis iniB gene
(Table 2). No products were visualized in
the primer extensions of BCG RNA that had not been treated with
isoniazid. A single product was detected after primer extension of RNA
from isoniazid treated BCG. The band was situated 45 bp upstream of the
likely translational start site (position 409308) (Fig.
6). Primer extensions performed with two additional primers complementary to other iniB gene
sequences (iniBprimer ext-1 and iniBprimer ext-2) yielded identical
results (not shown). The complete absence of product from the RNA that was not treated with INH was confirmed by prolonged exposure of the
gels. This result is consistent with previously described Northern blot
hybridizations of M. tuberculosis in which no
iniA RNA was detected unless the samples were treated with
INH (3).

View larger version (64K):
[in this window]
[in a new window]
|
FIG. 6.
Mapping the transcriptional start sites of the
iniBAC operon. Primer extension experiments were performed
with end-labeled iniBprimer ext-3 using either no RNA or RNA isolated
from BCG cultured in the absence of INH (INH ) or in the presence of
INH at a final concentration of 1 µg/ml (INH+). Sequencing reactions
were performed with the identical primer and run alongside the primer
extension reactions.
|
|
Deletion analysis of the iniBAC promoter.
The
induction kinetics of the 211-bp M. tuberculosis iniBAC
promoter region was investigated in M. smegmatis using
strain mc2155(pG4799-12). This strain contained the
full-length M. tuberculosis promoter region cloned into the
integrating vector pCV125 upstream of lacZ. We observed that
M. smegmatis had an induction phenotype similar to that of
BCG, although higher concentrations of INH were required because
M. smegmatis is relatively INH resistant. Induction by INH
(100 µg/ml) and 5 ethambutol (5 µg/ml) was seen as early as 30 min
after incubation with antibiotics and was maximal after 4 h of
incubation. These conditions were used to investigate the amount of
upstream DNA sequence that was required to induce the
-galactosidase
reporter. Inserts containing serial 19 to 25-bp 5' deletions of the
211-bp promoter region were cloned into pCV125 (Fig.
7A), and
-galactosidase activity was
measured. Induction by both antibiotics was preserved until a 22-bp
region 169 to 147 bp upstream from the translational start site (409184 to 409206) was deleted. After deletion of this sequence, both induction
and uninduced expression fell to levels of the promoterless plasmid control (Fig. 7B).

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 7.
Effect of promoter deletions on antibiotic induction.
Serial 5' and 3' deletions of the 211-bp sequence immediately upstream
of the translational start site of iniB were fused to the
lacZ gene in the integrating plasmid pCV125 and transformed
into M. smegmatis strain mc2155. (A) Schematic
of promoter deletions and induction after 4 h of treatment with
either INH (100 µg/ml) or ethambutol (EMB; 5 µg/ml). The dotted
line indicates the position of a 19-bp spacer that is unrelated to the
sequence it replaced; induction represents mean results from at least
three experiments. Numbering corresponds to the distance from the
translational start site. (B) -Galactosidase activity of promoter
deletions without (grey) or with (black) 4 h of incubation with
INH (100 µg/ml). Values represent means of at least three
experiments. Error bars represent 95% confidence intervals.
|
|
Effects of downstream deletions between the promoter and the
translational start site were investigated using serial 3' deletions (Fig. 7A). Interestingly, a 19-bp deletion 1 to 19 bp from the translational start site (409353 to 409334) increased induction from
4.5- to 13-fold for INH, and from 19- to 53-fold for ethambutol, without changing uninduced expression. The increased induction was not
due to changes in the spacing between the promoter and the
translational start site of the iniB gene. The higher level of induction continued to be observed after the absolute size of the
promoter sequence was restored by replacing the 19-bp 3' deletion with
a 19-bp spacer sequence that was unrelated to the promoter sequence.
Further 3' deletions preserved induction until a 26-bp sequence 39 to
65 bp from the translational start site (409314 to 409288) was removed.
When this last sequence was deleted, induction and uninduced expression
fell to levels of the promoterless plasmid (Fig. 7B).
 |
DISCUSSION |
The iniBAC operon encodes genes that are induced
specifically by a broad range of antibiotics that inhibit cell wall
biosynthesis. With the exception of cycloserine, the promoter was
induced by all clinically relevant antibiotics that act on the M. tuberculosis cell wall. Other toxic stimuli did not induce the
promoter, demonstrating the specificity of induction. Significant
repression of luciferase activity was observed after treatment with a
number of toxic agents that do not act by cell wall inhibition. It is
likely that the decreased availability of intracellular ATP levels in
the dying cells contributed to this effect.
With the exception of general stress responses, it is extremely
uncommon for antibiotics with different mechanisms of action to induce
the same set of genes in bacteria. VanA-type vancomycin resistance can
be induced by different antibiotics that inhibit cell wall synthesis,
possibly through the binding of peptidoglycan precursors in a
two-component regulatory system (4, 22, 40). AmpC, the
chromosomal
-lactamase in gram-negative bacteria, is induced by
different
-lactam antibiotics. Induction is oppositely controlled by
cytoplasmic concentrations of biosynthetic and degradative intermediates of murein metabolism (muropeptides) (21).
However, VanA-type vancomycin resistance is also induced by cell wall
hydrolytic enzymes such as lysozyme (40). We found that the
iniBAC promoter was not induced by either lysozyme or
granulysin, a molecule released by cytotoxic CD8+
lymphocytes that directly kills extracellular M. tuberculosis by altering the membrane integrity of the bacillus
(35). The ampC gene is induced by different
-lactam antibiotics, but these compounds are likely to have similar
mechanisms of action. In contrast, the iniBAC promoter is
induced by cell wall biosynthesis inhibitors that act on different
components of the cell wall. It is possible that the iniBAC
operon is induced by osmotic stress; however, we believe this to be
unlikely. While antibiotics might lead to alterations in permeability
of the bacterial cell wall and subsequent osmotic shock, both lysozyme
and granulysin would also be expected to result in permeability
changes. Neither of these compounds led to induction of the promoter,
suggesting that a different mechanism is involved in induction.
The functions of the genes encoded by the iniBAC operon are
unknown. The iniB gene has weak homology to cell wall
structural proteins. The iniA and iniC genes are
hypothetical proteins with no close homologs (3). Given the
induction pattern of this operon, it is possible that these genes
participate in the regulation of cell wall growth. It is also possible
that the iniBAC operon has either a causal or a protective
role in cell death, when killing is initiated by inhibition of cell
wall biosynthesis. Induction of the iniBAC operon was not
detectable until 4 h of incubation with antibiotics; in contrast,
induction of the FAS-II complex and most of the other genes known to be
INH induced occurs as early as 20 min after exposure to INH
(42). The delay in iniBAC induction corresponds
to the time required for INH to decrease the viability of M. tuberculosis in culture (37), suggesting a link between
the iniBAC operon and cell death. The rapid induction kinetics of the FAS-II complex and other INH-induced genes closely parallel the repressive effect of INH on mycolate biosynthesis (37). This suggests that unlike the iniBAC
operon, these genes are induced by events related to the initial
binding of INH to its target. The genes of the iniBAC operon
lack close homologs in nonmycobacterial species. However, the
iniA and iniB genes were detectable by
low-stringency hybridization in the fast-growing and avirulent M. smegmatis and in both virulent and avirulent slow-growing
mycobacteria. It is intriguing that only M. avium did not
hybridize to either gene probe. It remains possible that these genes
are present in M. avium but have insufficient homology to be
detected by this method.
Deletion studies of the region upstream of the coding sequences
demonstrate that regulatory elements essential for gene expression are
located in two regions, an upstream region 169 to 147 bp 5' from the
translational start site (409184 to 409206) and a downstream region 65 to 39 bp 5' from the translational start site (409314 to 409288) (Fig.
8). The upstream region contains a 10-bp
sequence flanked by 6-bp inverted repeats and part of two tandem 8-bp
direct repeats. Deletion of this region resulted in decreased
induction, suggesting the presence of UP elements, curved sequences, or
bent sequences that could influence initiation of transcription
(32). The downstream region includes both the
transcriptional start site and a sequence with strong homology to
10
promoter sequences (9, 29). The decreased induction that
resulted from deletion of this region is in agreement with observations
in E. coli that changes (or deletions) in the
10 region
and the region immediately downstream of the transcriptional start site
strongly influence promoter strength (32). The observation
that induction can be increased by deleting the 19-bp 3' end of this
promoter region is intriguing and suggests possible binding of a
transcriptional repressor downstream of the transcriptional start site.
The increased induction is sequence specific and not due to a change in
spacing because replacement of the deletion with a spacer sequence does not alter the increased induction that was observed. Database analysis
of regulatory sites has shown that the region downstream of
30 binds
repressors almost exclusively, whereas activators bind predominantly to
positions between
80 and
30 (18). The possibility that a
repressor protein binds to this region is currently being investigated.
The repressor sequence also appears to include a ribosomal binding
site. It is possible that a second, less apparent ribosomal binding
site could exist upstream of this sequence.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 8.
Proposed organization of iniBAC promoter
region. Regions found to be essential for induction are underlined with
solid lines; the dotted underline indicates the sequence whose deletion
leads to increased induction. Also shown are the transcriptional start
site (arrowhead), 6-bp inverted repeats (solid arrows), 8-bp direct
repeats (dotted arrows), the position of the primer iniBprimer ext-3
used in the primer extension experiments (striped arrow), and possible
10 sequence and ribosomal binding site (rbs). The asterisk marks an
alternate translational start site as annotated by Cole et al.
(16; NCBI database).
|
|
The reporter assays that we describe can be easily adapted to a 96-well
plate or solid-phase format. These assays can be used for
high-throughput screening of combinatorial libraries with the aim of
discovering new classes of compounds that inhibit
Mycobacterium cell wall biosynthesis. Assays that are
specific for cell wall inhibition may be more useful at finding
biologically active compounds than simple screens for inhibition or
killing of M. tuberculosis. When testing for inhibitory or
cidal compounds through repression of the constitutive luciferase
reporter strain BCG(pKB15), highly effective drugs such as INH resulted
in little inhibition of luciferase activity. Furthermore, these
antibiotics were indistinguishable from relatively ineffective agents
such as paraminosalicylic acid using the BCG(pKB15) assay (Fig. 1B).
In conclusion, the iniBAC operon is specifically induced by
inhibitors of cell wall biosynthesis. Regulation of transcription is
likely to be complex, involving both activator and repressor molecules.
Further investigation of the regulatory elements of the
iniBAC operon can potentially improve the understanding of the intracellular mechanisms that are activated by cell wall
inhibition. Characterization of the proteins encoded by the
iniB, iniA, and iniC genes may aid in
the development of new antibiotics that may be effective alone or
synergistically with other cell wall-active drugs.
We thank Barry R. Bloom and Oren Zimhony for advice and support,
and we thank Rosaria Cerny for laboratory assistance. We also thank
Graham Hatfull and MedImmune Inc. for use of unpublished vectors,
Robert Modlin for his gift of granulysin, and J. P. Welsh for his
gift of 5-chloropyrazinamide.
This work was supported by National Institutes of Health grants AI45244
and AI43268 and by the Howard Hughes Medical Research Institute.
| 1.
|
Ad Hoc Committee of the Scientific Assembly on Microbiology, Tuberculosis, and Pulmonary Infections.
1995.
Treatment of tuberculosis and tuberculosis infection in adults and children.
Clin. Infect. Dis.
21:9-27.
|
| 2.
|
Alland, D.,
G. E. Kalkut,
A. R. Moss,
R. A. McAdam,
J. A. Hahn,
W. Bosworth,
E. Drucker, and B. R. Bloom.
1994.
Transmission of tuberculosis in New York City: an analysis by DNA fingerprinting and conventional epidemiologic methods.
N. Engl. J. Med.
330:1710-1716[Abstract/Free Full Text].
|
| 3.
|
Alland, D.,
I. Kramnik,
T. R. Weisbrod,
L. Otsubo,
L. P. Miller,
W. R. Jacobs, Jr., and B. R. Bloom.
1998.
Identification of differentially expressed mRNA in prokaryotic organisms by customized amplification libraries (DECAL): the effect of isoniazid on gene expression in Mycobacterium tuberculosis.
Proc. Nat. Acad. Sci. USA
22:13227-13232.
|
| 4.
|
Allen, N. E., and J. N. Hobbs.
1995.
Induction of vancomycin resistance in Enterococcus faecium by non-glycopeptide antibiotics.
FEMS Microbiol. Lett.
132:107-114[CrossRef][Medline].
|
| 5.
|
Arthur, M.,
C. Molinas, and P. Courvalin.
1992.
The VanK-VanR two-component regulatory system controls synthesis of depsipeptide peptidoglycan precursors in Enterococcus faecium BM4147.
J. Bacteriol.
174:2582-2591[Abstract/Free Full Text].
|
| 6.
|
Balasubramanian, V.,
M. S. Pavelka, Jr.,
S. S. Bardarov,
J. Martin,
T. R. Weisbrod,
R. A. McAdam,
B. R. Bloom, and W. R. Jacobs, Jr.
1996.
Allelic exchange in Mycobacterium tuberculosis with long linear recombination substrates.
J. Bacteriol.
178:273-279[Abstract/Free Full Text].
|
| 7.
|
Banerjee, A.,
E. Dubnau,
A. Quemard,
V. Balasubramanian,
K. S. Um,
T. Wilson,
D. Collins,
G. de Lisle, and W. R. Jacobs, Jr.
1994.
inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis.
Science
263:227-230[Abstract/Free Full Text].
|
| 8.
|
Bange, F. C.,
A. M. Brown, and W. R. Jacobs, Jr.
1996.
Leucine auxotrophy restricts growth of Mycobacterium bovis BCG in macrophages.
Infect. Immun.
64:1794-1799[Abstract].
|
| 9.
|
Bashym, M. D.,
D. Kaushal,
D. K. Sujoy, and A. K. Tyagi.
1996.
A study of the mycobacterial transcriptional apparatus: identification of novel features in promoter elements.
J. Bacteriol.
178:4847-4853[Abstract/Free Full Text].
|
| 10.
|
Besra, G. S.,
C. B. Morehouse,
C. M. Rittner,
C. J. Waechter, and P. J. Brennan.
1997.
Biosynthesis of mycobacterial lipoarabinomannan.
J. Biol. Chem.
272:18460-18466[Abstract/Free Full Text].
|
| 11.
|
Besra, G. S., and P. J. Brennan.
1997.
The mycobacterial cell wall: biosynthesis of arabinogalactan and lipoarabinomannan.
Biochem. Soc. Trans.
25:845-850[Medline].
|
| 12.
|
Belanger, A. E.,
G. S. Besra,
M. E. Ford,
K. Mikusova,
J. T. Belisle,
P. J. Brennan, and J. M. Inamine.
1996.
The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol.
Proc. Natl. Acad. Sci. USA
93:11919-11924[Abstract/Free Full Text].
|
| 13.
|
Best, G. K.,
N. H. Best, and A. V. Koval.
1974.
Evidence of participation of autolysins in bactericidal action of oxacillin of Staphylococcus aureus.
Antimicrob. Agents Chemother.
6:825-830[Abstract/Free Full Text].
|
| 14.
|
Brown, P. O., and D. Botstein.
1999.
Exploring the new world of the genome with DNA microarrays.
Nat. Genet.
21:33-37[CrossRef][Medline].
|
| 15.
|
Centers for Disease Control.
1993.
Estimates of future global tuberculosis morbidity and mortality.
Morbid. Mortal. Weekly Rep.
42:961-964[Medline].
|
| 16.
|
Cole, S. T.,
R. Brosch,
J. Parkhill,
T. Garnier,
C. Churcher,
D. Harris,
S. V. Gordon,
L. Eiglmeier,
S. Gas,
C. E. Barry III,
F. Tekaia,
K. Badcock,
D. Basham,
D. Brown,
T. Chillingworth,
R. Connor,
R. Davies,
K. Devlin,
T. Feltwell,
S. Gentles,
N. Hamlin,
S. Holroyd,
T. Hornsby,
K. Jagels,
B. G. Barrell, et al.
1998.
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence.
Nature
393:537-544[CrossRef][Medline].
|
| 17.
|
Fischl, M. A.,
R. B. Uttamchandani,
G. L. Daikos,
R. B. Poblete,
J. N. Moreno, and R. R. Reyes.
1992.
An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection.
Ann. Intern. Med.
117:177-183.
|
| 18.
|
Gralla, J. D., and J. Collado-Vides.
1996.
Organization and function of transcription regulatory elements, p. 1232-1245.
In
F. C. Neidhardt, R. Curtiss III, J. L. Ingraham, E. C. C. Lin, K. B. Low, B. Magasanik, W. S. Reznikoff, M. Riley, M. Schaechter, and H. E. Umbarger (ed.), Escherichia coli and Salmonella: cellular and molecular biology, 2nd ed., vol. 1. ASM Press, Washington, D.C.
|
| 19.
|
Horne, D., and A. Tomasz.
1977.
Tolerant response of Streptococcus sanguis to beta-lactams and other cell wall inhibitors.
Antimicrob. Agents Chemother.
11:888-896[Abstract/Free Full Text].
|
| 20.
|
Hu, Y., and A. R. M. Coates.
1999.
Transcription of two sigma 70 homologue genes, sigA and sigB, in stationary-phase Mycobacterium tuberculosis.
J. Bacteriol.
181:469-476[Abstract/Free Full Text].
|
| 21.
|
Jacobs, C.,
J. M. Frere, and S. Normark.
1997.
Cytosolic intermediates for cell wall biosynthesis and degradation control inducible biosynthesis and degradation control inducible -lactam resistance in gram-negative bacteria.
Cell
88:823-832[CrossRef][Medline].
|
| 22.
|
Lai, M. H., and D. R. Kirsch.
1996.
Induction signals for vancomycin resistance encoded by the vanA gene cluster in Enterococcus faecium.
Antimicrob. Agents Chemother.
40:1645-1648[Abstract].
|
| 23.
|
Lee, R. E.,
P. J. Brennan, and G. S. Besra.
1996.
Mycobacterium tuberculosis cell envelope.
Curr. Top. Microbiol. Immunol.
215:1-27[Medline].
|
| 24.
|
Mandell, G. E.,
G. R. Douglas, Jr., and J. E. Bennett.
1995.
Principles and practice of infectious diseases, 4th ed.
Churchill Livingstone, New York, N.Y.
|
| 25.
|
Mdluli, K.,
R. A. Slayden,
Y. Zhu,
S. Ramaswamy,
X. Pan,
D. Mead,
D. D. Crane,
J. M. Musser, and C. E. Barry, III.
1998.
Inhibition of a Mycobacterium tuberculosis -ketoacyl ACP synthase by isoniazid.
Science
280:1607-1710[Abstract/Free Full Text].
|
| 26.
|
Movahedzadeh, F.,
J. M. Colston, and E. O. Davis.
1997.
Determination of DNA sequences required for regulated Mycobacterium tuberculosis RecA expression in response to DNA-damaging agents suggests that two modes of regulation exist.
J. Bacteriol.
179:3509-3518[Abstract/Free Full Text].
|
| 27.
|
Michele, T. M.,
C. Ko, and W. R. Bishai.
1999.
Exposure to antibiotics induces expression of the Mycobacterium tuberculosis sigF gene: implications for chemotherapy against mycobacterial persistors.
Antimicrob. Agents Chemother.
43:218-225[Abstract/Free Full Text].
|
| 28.
|
Mikusova, K.,
M. Mikus,
G. S. Besra,
I. Hancock, and P. J. Brennan.
1996.
Biosynthesis of the linkage region of the mycobacterial cell wall.
J. Biol. Chem.
271:7820-7828[Abstract/Free Full Text].
|
| 29.
|
Mulder, M. A.,
H. Zappe, and L. M. Steyn.
1997.
Mycobacterial promoters.
Tuberc. Lung Dis.
78:211-223[CrossRef][Medline].
|
| 30.
|
Pablos-Mendez, A.,
M. C. Raviglione,
A. Laszlo,
N. Binkin,
H. L. Rieder,
F. Bustreo,
D. L. Cohn,
C. S. Lambregts-van Weezenbeek,
S. J. Kim,
P. Chaulet, and P. Nunn.
1998.
Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.
N. Engl. J. Med.
338:1641-1649[Abstract/Free Full Text].
|
| 31.
|
Pascopella, L.,
F. M. Collins,
J. M. Martin,
M. H. Lee,
G. F. Hatfull,
C. K. Stover,
B. R. Bloom, and W. R. Jacobs, Jr.
1994.
Use of in vivo complementation in Mycobacterium tuberculosis to identify a genomic fragment associated with virulence.
Infect. Immun.
62:1313-1319[Abstract/Free Full Text].
|
| 32.
|
Record, M. T., Jr.,
W. S. Reznikoff,
M. L. Craig,
K. L. McQuade, and P. J. Schlax.
1996.
Escherichia coli RNA polymerase (E 70), promoters, and the kinetics of the steps of transcription initiation, p. 792-820.
In
F. C. Neidhardt, R. Curtiss III, J. L. Ingraham, E. C. C. Lin, K. B. Low, B. Magasanik, W. S. Reznikoff, M. Riley, M. Schaechter, and H. E. Umbarger (ed.), Escherichia coli and Salmonella: cellular and molecular biology, 2nd ed., vol. 1. ASM Press, Washington, D.C.
|
| 33.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
|
| 34.
|
Snapper, S. B.,
R. E. Melton,
S. Mustafa,
T. Kieser, and W. R. Jacobs, Jr.
1990.
Isolation and characterization of efficient plasmid transformation mutants of Mycobacterium smegmatis.
Mol. Microbiol.
4:1911-1919[Medline].
|
| 35.
|
Stenger, S.,
D. A. Hanson,
R. Teitelbaum,
P. Dewan,
K. R. Niazi,
C. J. Froelich,
T. Ganz,
S. Thoma-Uszynski,
A. Melian,
C. Bogdan,
S. A. Porcelli,
B. R. Bloom,
A. M. Krensky, and R. L. Modlin.
1998.
An antimicrobial activity of cytolytic T cells mediated by granulysin.
Science
282:121-125[Abstract/Free Full Text].
|
| 36.
|
Stover, C. K.,
V. F. de la Cruz,
T. R. Fuerst,
J. E. Burlein,
L. A. Benson,
L. T. Bennett,
G. P. Bansal,
J. F. Young,
M. H. Lee,
G. F. Hatfull, et al.
1991.
New use of BCG for recombinant vaccines.
Nature
351:456-460[CrossRef][Medline].
|
| 37.
|
Takayama, K.,
L. Wang, and D. L. Hugo.
1972.
Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis.
Antimicrob. Agents Chemother.
2:29-35[Abstract/Free Full Text].
|
| 38.
|
Telenti, A.,
W. J. Philipp,
S. Sreevatsan,
C. Bernasconi,
K. E. Stockbauer,
B. Wieles, et al.
1997.
The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol.
Nat. Med.
3:567-570[CrossRef][Medline].
|
| 39.
|
Tomasz, A.,
A. Albino, and E. Zanati.
1970.
Multiple antibiotic resistance in a bacterium with suppressed autolytic system.
Nature
227:138-140[CrossRef][Medline].
|
| 40.
|
Ulijasz, A. T.,
A. Grenader, and B. Weisblum.
1996.
A vancomycin-inducible LacZ reporter system in Bacillus subtilis: induction by antibiotics that inhibit cell wall synthesis and by lysozyme.
J. Bacteriol.
178:6305-6309[Abstract/Free Full Text].
|
| 41.
|
Via, L. E.,
R. Curcic,
M. H. Mudd,
S. Dhandayuthapani,
R. J. Ulmer, and V. Deretic.
1996.
Elements of signal transduction in Mycobacterium tuberculosis: in vitro phosphorylation and in vivo expression of the response regulator MtrA.
J. Bacteriol.
178:3314-3321[Abstract/Free Full Text].
|
| 42.
|
Wilson, M.,
J. DeRisi,
H. H. Kristensen,
P. Imboden,
S. Rane,
P. O. Brown, and G. K. Schoolnik.
1999.
Exploring drug-induced alterations in gene expression in mycobacterium tuberculosis by microarray hybridization.
Proc. Natl. Acad. Sci. USA
96:12833-12838[Abstract/Free Full Text].
|
| 43.
|
Zhang, Y.,
B. Heym,
B. Allen,
D. Young, and S. Cole.
1992.
The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis.
Nature
358:591-593[CrossRef][Medline].
|